Virtual Grand Rounds: Bipolar Disorder Comorbid Conditions
Presented by:
Mauricio Tohen, MD, DrPH, MBA
University Distinguished Professor and Chairman
Department of Psychiatry and Behavioral Sciences
University of New Mexico School of Medicine
Dr. Tohen will review the most frequent comorbid conditions associated with bipolar disorder.
Educational Objectives
As a result of participating in this activity, learners should be able to:
- Describe what is the most frequent comorbid disorder associated with bipolar disorder
- Describe the prevalence of comorbid substance use disorder in patient with first episode of mania
- Describe the prevalence of comorbidity of anxiety disorder, and SUD disorder and bipolar disorder
After registering, you will receive a confirmation email containing information about joining the Zoom webinar.
Accreditation Statement: Silver Hill Hospital is accredited by the Massachusetts Medical Society to provide continuing medical education for physicians.
Designation Statement: Silver Hill Hospital designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
NASW/Connecticut Statement: This program has been approved for 1.5 Continuing Education Credit Hours by the National Association of Social Workers, CT and meets the continuing education criteria for CT Social Work Licensure renewal. Approval also meets the continuing education criteria for CT LMFTs, LPCs, and licensed psychologists.
New York Social Worker Statement: Silver Hill Hospital is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0728. This program is approved for 1.5 contact hours.
New York Psychologist Statement: Silver Hill Hospital is recognized by the New York State Education Department’s State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY-0227. This program is approved for 1.5 contact hours.
Speaker Disclosure: Dr. Tohen has received honoraria from or consulted for Abbott, Abbvie, AstraZeneca, Alkermes, Atai, Biohaven Pharmaceuticals, Squibb, Rapport Neurosciences, Lilly, Johnson & Johnson, Otsuka, Merck, Sunovion, Intra-Cellular Therapies, NeuroRX, Roche, Elan, Lundbeck, Teva, Minerva, NeurocrineBiosciences, NoemaPharma, Pfizer. Any relevant financial relationships with an ACCME defined commercial interest have been mitigated and there are no conflicts of interest or bias.
No planners of this activity have indicated a relevant financial relationship with an ACCME defined commercial interest.